• Je něco špatně v tomto záznamu ?

Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma

A. Poprach, I. Kiss, M. Stanik, T. Barusova, L. Pospisilova, O. Fiala, J. Kopecky, I. Richter, B. Melichar, H. Studentova, R. Lakomy, M. Holanek, A. Rozsypalova, A. Zemanková, M. Svoboda, T. Buchler

. 2023 ; 18 (6) : 893-903. [pub] 20231113

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000768

Grantová podpora
NU21-03-00539 Ministerstvo Zdravotnictví Ceské Republiky

E-zdroje Online Plný text

NLK ProQuest Central od 2006-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2006-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 2006-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2006-01-01 do Před 1 rokem
Family Health Database (ProQuest) od 2006-01-01 do Před 1 rokem

Odkazy

PubMed 37957520
DOI 10.1007/s11523-023-01013-0
Knihovny.cz E-zdroje

BACKGROUND: Treatment options for metastatic renal cell carcinoma (mRCC) are rapidly expanding, and immunotherapy using checkpoint inhibitors is a first- or second-line option for most patients. OBJECTIVE: The objective of the present retrospective analysis was to explore the real-world impact of checkpoint inhibitor-based immunotherapy compared with therapy using other types of targeted therapies using a large real-world database. METHODS: RenIS, a registry of patients with mRCC was used as a data source. Outcomes were compared for cohorts treated with TKIs or mTOR inhibitors only [targeted therapy (TT) cohort] versus patients who received immunotherapy (IO) using a checkpoint inhibitor in any line of treatment (IO cohort). Data from a total of 1981 patients were extracted from the registry, including 1767 patients in the TT cohort and 214 patients in the IO cohort. RESULTS: The median overall survival from the initiation of first-line treatment was 24.5 months versus not reached (p < 0.001) in the TT cohort versus the IO cohort, respectively [HR 0.23, 95% CI (0.17-0.31), p < 0.001]. The probability of 5-year survival was 24.2 versus 67.9% in the TT cohort versus the IO cohort, respectively. Immunotherapy in any line of treatment was associated with a lower risk of death. Overall survival was superior for patients receiving immunotherapy as the first or second treatment line compared with patients treated with non-immunological targeted therapy. CONCLUSION: In real-world patients with mRCC, immunotherapy is associated with significant survival benefit. The present retrospective analysis shows the real-world benefit of second-line immunotherapy in patients previously treated with tyrosine-kinase inhibitors.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000768
003      
CZ-PrNML
005      
20240213093351.0
007      
ta
008      
240109s2023 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11523-023-01013-0 $2 doi
035    __
$a (PubMed)37957520
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic
245    10
$a Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma / $c A. Poprach, I. Kiss, M. Stanik, T. Barusova, L. Pospisilova, O. Fiala, J. Kopecky, I. Richter, B. Melichar, H. Studentova, R. Lakomy, M. Holanek, A. Rozsypalova, A. Zemanková, M. Svoboda, T. Buchler
520    9_
$a BACKGROUND: Treatment options for metastatic renal cell carcinoma (mRCC) are rapidly expanding, and immunotherapy using checkpoint inhibitors is a first- or second-line option for most patients. OBJECTIVE: The objective of the present retrospective analysis was to explore the real-world impact of checkpoint inhibitor-based immunotherapy compared with therapy using other types of targeted therapies using a large real-world database. METHODS: RenIS, a registry of patients with mRCC was used as a data source. Outcomes were compared for cohorts treated with TKIs or mTOR inhibitors only [targeted therapy (TT) cohort] versus patients who received immunotherapy (IO) using a checkpoint inhibitor in any line of treatment (IO cohort). Data from a total of 1981 patients were extracted from the registry, including 1767 patients in the TT cohort and 214 patients in the IO cohort. RESULTS: The median overall survival from the initiation of first-line treatment was 24.5 months versus not reached (p < 0.001) in the TT cohort versus the IO cohort, respectively [HR 0.23, 95% CI (0.17-0.31), p < 0.001]. The probability of 5-year survival was 24.2 versus 67.9% in the TT cohort versus the IO cohort, respectively. Immunotherapy in any line of treatment was associated with a lower risk of death. Overall survival was superior for patients receiving immunotherapy as the first or second treatment line compared with patients treated with non-immunological targeted therapy. CONCLUSION: In real-world patients with mRCC, immunotherapy is associated with significant survival benefit. The present retrospective analysis shows the real-world benefit of second-line immunotherapy in patients previously treated with tyrosine-kinase inhibitors.
650    _2
$a lidé $7 D006801
650    12
$a karcinom z renálních buněk $x farmakoterapie $7 D002292
650    12
$a nádory ledvin $x farmakoterapie $x patologie $7 D007680
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a protokoly protinádorové kombinované chemoterapie $7 D000971
650    _2
$a imunoterapie $7 D007167
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kiss, Igor $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic
700    1_
$a Stanik, Michal $u Department of Urologic Oncology, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic
700    1_
$a Barusova, Tamara $u Institute of Biostatistics and Analyses Brno, Brno, Czech Republic
700    1_
$a Pospisilova, Lenka $u Institute of Biostatistics and Analyses Brno, Brno, Czech Republic
700    1_
$a Fiala, Ondrej $u Department of Oncology and Radiotherapy, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Faculty of Medicine in Pilsen, Biomedical Centre, Charles University, Pilsen, Czech Republic
700    1_
$a Kopecky, Jindrich $u University Hospital in Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Richter, Igor $u Department of Oncology, Liberec Regional Hospital, Liberec, Czech Republic
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic
700    1_
$a Studentova, Hana $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic
700    1_
$a Lakomy, Radek $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic
700    1_
$a Holanek, Milos $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic
700    1_
$a Rozsypalova, Aneta $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
700    1_
$a Zemanková, Anezka $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic
700    1_
$a Svoboda, Marek $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic
700    1_
$a Buchler, Tomas $u Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, V Uvalu 84, 150 06, Prague, Czech Republic. tomas.buchler@fnmotol.cz $1 https://orcid.org/000000016667994X $7 xx0096851
773    0_
$w MED00189571 $t Targeted oncology $x 1776-260X $g Roč. 18, č. 6 (2023), s. 893-903
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37957520 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093348 $b ABA008
999    __
$a ok $b bmc $g 2049410 $s 1210462
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 18 $c 6 $d 893-903 $e 20231113 $i 1776-260X $m Targeted oncology $n Target Oncol $x MED00189571
GRA    __
$a NU21-03-00539 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace